MMP inhibition prevents human lens epithelial cell migration and contraction of the lens capsule
- 1Wound Healing Research Unit, Department of Pathology, Institute of Ophthalmology, London, UK
- 2Moorfields Eye Hospital, London, UK
- Correspondence to: Dr T T L Wong Ocular Repair and Regeneration Biology, Department of Pathology, Institute of Ophthalmology, 11–43 Bath Street, London EC1V 9EL, UK; tina.wongucl.ac.uk
- Accepted 30 November 2003
Abstract
Purpose: The development of posterior capsule contraction following cataract surgery is caused by the activity of residual lens epithelial cells. Matrix metalloproteinases (MMPs) are a group of proteolytic enzymes, which are essential for cell migration and cell mediated contraction following wound healing. The authors investigated whether inhibiting MMP activity can reduce lens epithelial cell migration and as a result, lead to a reduction in cell mediated capsule contraction.
Methods: Human donor lens capsules were cultured and treated with a broad spectrum MMP inhibitor, Ilomastat (GM6001). MMP-2 and MMP-9 production were determined by ELISA. Cell migration onto the posterior capsule and capsule contraction were digitally measured.
Results: MMP inhibition significantly reduced lens epithelial cell migration onto the posterior capsule (p<0.05), and a reduction in capsule contraction was observed (p<0.05).
Conclusions: Ilomastat significantly reduced lens epithelial cell migration onto the posterior capsule surface and inhibited capsule contraction. MMP inhibition may have a role in the therapeutic treatment of posterior capsule opacification.
- DMEM, Dulbecco’s modified Eagle’s medium
- FCS, fetal calf serum
- LECs, lens epithelial cells
- MMP, matrix metalloproteinase
- PBS, phosphate buffered saline
- PCO, posterior capsule opacification
- matrix metalloproteinase
- posterior capsule opacification
- matrix contraction
- DMEM, Dulbecco’s modified Eagle’s medium
- FCS, fetal calf serum
- LECs, lens epithelial cells
- MMP, matrix metalloproteinase
- PBS, phosphate buffered saline
- PCO, posterior capsule opacification
- matrix metalloproteinase
- posterior capsule opacification
- matrix contraction
Footnotes
-
This work has been funded by the Wellcome Trust, UK (Grant number 060134; TTLW), Royal National Institute for the Blind, UK (JTD), the Medical Research Council, UK (G9330070; PTK), and the Haymans Trust, London, UK.









